The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.
|Articles|October 23, 2020
In case you missed it: October 19 to October 23
It was a very busy week for the Contemporary Pediatrics team.
Advertisement
This week’s top articles included:
A number of abnormal head shapes can occur during development in the womb. A recent guide is available to help pediatricians assess these issues and understand when to seek a referral.
A report examines the impact of Medicaid funding on how many neonates undergo circumcision.
An investigation examines how governmental spending, in both health and nonhealth areas, can impact infant mortality rates.
An investigation looks into whether exposure to maternal epidural during delivery has an impact on risk for autism spectrum disorder.
Advertisement
Related to this article
FDA accepts leniolisib sNDA with priority review for children with APDS aged 4+ weighing 13 to <27 kg; PDUFA date is January 30, 2027.
FDA approves oral ALK2 inhibitor zilurgisertib for FOP in patients 12+, based on phase 2 PROGRESS data on new heterotopic ossification volume.
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA grants priority review to leniolisib sNDA for lower-weight children with APDS
2
FDA approves zilurgisertib for fibrodysplasia ossificans progressiva in patients aged 12 years and older
3
Gut Microbiome, Immune Programming, and Allergic Disease Risk
4
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
5